Eli Lilly and Co
LLY
Company Profile
- Business description- Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. 
- Contact- Lilly Corporate Center 
 IndianapolisIN46285
 USA- T: +1 317 276-2000 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Drug Manufacturers - General - Fiscal Year End- 31 December 2025 - Employees- 47,000 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,157.29 | 43.59 | -0.53% | 
| DAX 40 | 24,118.89 | 5.32 | -0.02% | 
| Dow JONES (US) | 47,522.12 | 109.88 | -0.23% | 
| FTSE 100 | 9,760.06 | 3.92 | 0.04% | 
| HKSE | 25,999.70 | 282.99 | -1.08% | 
| NASDAQ | 23,581.14 | 377.33 | -1.57% | 
| Nikkei 225 | 52,244.44 | 918.83 | 1.79% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,822.34 | 68.25 | -0.99% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,955.92 | 30.98 | -0.78% |